VR Logo

Graphite Bio Inc. (GRPH) download report


Healthcare | Biotechnology & Pharma Research

Graphite Bio Inc. (GRPH) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.

IPO Date: 25-Jun-2021

Pres, CEO & Director: Dr. Joshua Lehrer-Graiwer FACC, M.D.

Academic Founder & Director: Dr. Matthew Porteus M.D., Ph.D.

Listing: NASDAQ: GRPH

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.graphitebio.com

Key Facts

Market cap: $166.37 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-76.89 Mln

Cash: $339.18 Mln

Total Debt: $10.18 Mln

Insider's Holding: 9.55%

Liquidity: Low

52 Week range: $2.07 - 32.49

Shares outstanding: 57,970,100

Stock Performance

Time Period Graphite Bio (GRPH) S&P BSE Sensex S&P Small-Cap 600
YTD-77.35-8.99-19.23
1 month20.30-3.40-9.35
3 months-46.18-8.50-16.59
1 Year-89.800.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022